Stocktoria
Gossamer Bio, Inc. GOSS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-02-08
Gossamer Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Interest expense | — | — | $13.5M | $13.9M | $19.4M |
| Income tax | -$88,000 | $893,000 | $0 | $0 | — |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M |
| EPS (diluted) | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M |
| Cash & equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.4M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
| Shareholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M |
Source: SEC EDGAR filings · CIK 0001728117 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.